FIELD: medicine.
SUBSTANCE: method for prediction of the risk of breast cancer development in a female individual that does not suffer from breast cancer, includes: determination of the level of pro-neurotensin 1-117 with amino acid sequence represented on SEQ ID No. 5, or its fragments from at least 5 amino acids or peptides containing this pro-neurotensin 1-117, obtained from the biological fluid of the specified female individual, selected from the group consisting of blood, serum, plasma, urine, cerebrospinal fluid and saliva, where pro-neurotensin 1-117 level is determined on an empty stomach; and correlation of the specified level of pro-neurotensin 1-117 or its fragments, or peptides containing pro-neurotensin 1-117, with the risk of breast cancer development, where an elevated level is prognostic for the increased risk of breast cancer.
EFFECT: method allows to effectively predict the risk of breast cancer development in a female individual.
14 cl, 2 dwg, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING RISK OF GETTING CARDIOVASCULAR EVENT IN FEMALE SUBJECT | 2013 |
|
RU2652304C2 |
| METHOD FOR PREDICTING RISK OF SUBJECTS CONTRACTING DIABETES MELLITUS AND/OR METABOLIC SYNDROME OR FOR DIAGNOSING METABOLIC SYNDROME IN SUBJECTS | 2013 |
|
RU2685713C2 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING LUMINAL SUBTYPE OF BREAST CANCER IN WOMEN | 2024 |
|
RU2828523C1 |
| METHOD OF SELECTING WOMEN AT RISK OF DEVELOPING PERIMENOPAUSAL BREAST CANCER | 2019 |
|
RU2717148C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING BREAST CANCER IN WOMEN WITHOUT OBESITY BY RESULTS OF GENETIC TESTING | 2024 |
|
RU2828525C1 |
| METHOD FOR PREDICTING RISK OF GETTING CANCER OR DIAGNOSING CANCER IN FEMALE SUBJECT | 2013 |
|
RU2671578C2 |
| METHOD FOR PREDICTION OF RISK OF CANCER OR DIAGNOSING CANCER IN WOMAN | 2013 |
|
RU2707755C2 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING CANCER OR DIAGNOSING CANCER IN INDIVIDUAL | 2014 |
|
RU2701730C2 |
| METHOD TO PREDICT OBESITY RISK IN SUBJECT | 2016 |
|
RU2745751C2 |
| USE OF O-ACETYLATED GD2 GANGLIOSIDE AS TARGET AS NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACH IN MALIGNANT GROWTHS CONTAINING TUMOUR STEM CELLS | 2014 |
|
RU2702428C2 |
